(Reuters) - Bristol-Myers Squibb Co said it would invest in Dutch biotech uniQure NV to get access to uniQure's gene therapy technology platform for cardiovascular diseases. Bristol-Myers will pay at least $32 million to take a 4.9 percent stake in uniQure. UniQure will be eligible to receive milestone payments, including up to $254 million for the lead S100A1 therapeutic and up to $217 million for each other gene therapy product potentially developed under the deal. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment